Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inside ‘Case For Quality’ Forum: FDA Ponders ‘Critical-To-Quality’ Inspectional Approach

This article was originally published in The Silver Sheet

Executive Summary

FDA is considering focusing inspections on ‘critical-to-quality’ practices as part of its ‘Case for Quality’ initiative. A pilot will be launched this year to identify practices related to particular device types or quality system requirements, an agency official says. Critical-to-quality issues were just one topic discussed at an April 30 FDA national forum on the Case for Quality, which was off-limits to media. “The Silver Sheet” got the inside skinny from three industry experts who attended the meeting.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel